Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459524 · ClinicalTrials.gov registry record
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 104
- Enrollment target
NCT00459524: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00459524 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00459524 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 104 participants
- Enrollment target
Study Summary
Primary Objectives: * To compare the neuropsychiatric (NP) and neurocognitive (NC) symptoms and assess the quality of life (QOL) in older patients (age \> 18) with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) receiving different therapies, chemotherapy (Clofarabine + ara-C) or targeted therapies (PKC412 + low-dose ara-C, or R115777 + low-dose ara-C, or decitabine, or STI + low-dose ara-C). * To determine whether there is a correlation between the number of packed red blood cell (PRBC) transfusions and cognitive scores and/or QOL.
Interventions
- BEHAVIORAL Questionnaire
- BEHAVIORAL Neurocognitive Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2004-04 |
| Est. Completion | 2009-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00459524
The ClinicalTrials.gov registry entry for NCT00459524 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00459524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00459524 about?
NCT00459524 is a clinical study titled "Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)". Primary Objectives: * To compare the neuropsychiatric (NP) and neurocognitive (NC) symptoms and assess the quality of life (QOL) in older patients (age \> 18) with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) receiving different therapies, chemotherapy (Clofarabine +...
What is the current status of trial NCT00459524?
This trial is currently completed. The enrollment target is 104 participants. The study started on 2004-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00459524?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Neurocognitive Testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT00459524?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.